(NASDAQ: RXST) Rxsight's forecast annual revenue growth rate of 23.62% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Rxsight's revenue in 2024 is $128,293,000.On average, 5 Wall Street analysts forecast RXST's revenue for 2024 to be $5,638,917,089, with the lowest RXST revenue forecast at $5,620,860,689, and the highest RXST revenue forecast at $5,646,655,547. On average, 5 Wall Street analysts forecast RXST's revenue for 2025 to be $7,621,735,549, with the lowest RXST revenue forecast at $7,242,712,361, and the highest RXST revenue forecast at $8,058,474,732.
In 2026, RXST is forecast to generate $9,809,300,692 in revenue, with the lowest revenue forecast at $8,696,494,413 and the highest revenue forecast at $10,658,515,769.